NCT02684591View on ClinicalTrials.gov

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Nonalcoholic Fatty Liver DiseaseHIV
Interventions
DRUG

Aramchol

Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters

DRUG

Placebo

Placebo

Trial Locations (1)

92103

University of California, San Diego, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT02684591 - Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy | Biotech Hunter | Biotech Hunter